Posts - Bill - HR 1396 PILLS Act
house 02/14/2025 - 119th Congress
We are working to encourage domestic production of affordable generic drugs and biosimilars by offering tax credits to manufacturers, aiming to strengthen the supply chain and lower medicine costs.
Congress.gov
HR 1396 - PILLS Act
Views
moderate 02/14/2025
Smart incentives for domestic production could ease drug prices, but let’s watch for loopholes that lobbyists love to find.
right-leaning 02/14/2025
Less dependence on foreign pharma means more jobs here—good policy that rewards producers, not freeloaders.
right-leaning 02/14/2025
Tax credits for domestic drug production? Finally, a shot at cutting red tape and unleashing American innovation.
left-leaning 02/14/2025
Incentivizing drugmakers to bring generic meds back home? About time we put American patients before Big Pharma’s bottom line.
moderate 02/14/2025
Boosting biosimilars might shake up the market—but careful regulation is key to avoid unintended price hikes.
left-leaning 02/14/2025
This credit is a win for working families and a slap in the face to greedy corporations charging us an arm and a leg.
left-leaning 02/14/2025
Finally, a bill that puts people over profits by making lifesaving meds more affordable. Health care is a right, not a luxury—let’s make it real.
right-leaning 02/14/2025
This bill is a win for free enterprise, not endless government handouts—let the market drive lifesaving meds forward.
moderate 02/14/2025
A nudge toward US manufacturing sounds good on paper; let’s make sure the savings actually hit the consumer’s wallet.